An official website of the State of Oregon Learn How you know » (how to identify a Oregon.gov website) An official website of the State of Oregon »
You are here:
PDAB wants to hear from Oregonians about drug costs
The Oregon Prescription Drug Affordability Board (PDAB) is seeking input from patients, caregivers, and others about the cost of prescription medications. The board invites patients, caregivers, advocacy groups, medical professionals, manufacturers, safety net clinics, pharmacy benefit managers, and health plan insurers to submit a feedback form about the prescription drugs currently under board review: Jardiance; Mounjaro; Ozempic; Humulin R U-500; Keytruda; Verzenio; Xeljanz; Ocrevus; Skyrizi; Tremfya; and Xolair. If any of these medications have affected your health, finances, or communities, please share your experiences with the board. Your feedback will help inform PDAB’s review process. Click on the link below to select the applicable form, complete the questions, and submit the form. Thank you in advance for your participation.
The next PDAB meeting is:
Wednesday, June 17, 2026 8 A.M. Pacific Time
Register here
Agenda materials
About the PDAB
The Oregon Prescription Drug Affordability Board is established in the Department of Consumer and Business Services under ORS 646A.693 to protect residents of Oregon, state and local governments, commercial health plans, health care providers, pharmacies licensed in Oregon and others within the health care system in this state from the high costs of prescription drugs. To learn more about the board’s work, see the FAQ page.
A .gov website belongs to an official government organization in the United States.
A lock icon ( ) or https:// means you’ve safely connected to the .gov website.
Your browser is out-of-date! It has known security flaws and may not display all features of this and other websites. Learn how
×